实用心脑肺血管病杂志
實用心腦肺血管病雜誌
실용심뇌폐혈관병잡지
Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
2015年
10期
72-74
,共3页
陈佳权%崔玉梅%陈典%陈军
陳佳權%崔玉梅%陳典%陳軍
진가권%최옥매%진전%진군
癌,非小细胞肺%吉西他滨%顺铂%药物疗法,联合%治疗结果
癌,非小細胞肺%吉西他濱%順鉑%藥物療法,聯閤%治療結果
암,비소세포폐%길서타빈%순박%약물요법,연합%치료결과
Carcinoma,non - small - cell lung%Gemcitabine%Cisplatin%Drug therapy,combination%Treatment outcome
目的：分析吉西他滨联合顺铂动静脉化疗方案治疗晚期非小细胞肺癌（NSCLC）的临床疗效。方法选择恩施土家族苗族自治州中心医院2010年1月—2013年6月收治的晚期 NSCLC 患者70例，所有患者入院后给予吉西他滨联合顺铂动静脉化疗方案：吉西他滨1 g/ m2联合顺铂50 mg/ m2行支气管动脉灌注（BAI）治疗，第1天；吉西他滨1 g/ m2静脉滴注，第8天。28 d 为1个化疗周期，2个化疗周期后观察患者临床疗效及化疗期间毒副作用发生情况，并分析不同解剖分型及病理分型患者的临床疗效。结果70例晚期 NSCLC 患者中完全缓解5例，部分缓解38例，疾病稳定19例，疾病进展8例，有效率为61.4%。鳞癌患者临床疗效优于腺癌患者（u =2.004，P =0.045）、中央型患者临床疗效优于周围型患者（u =3.639，P =0.000）。化疗期间患者胸痛发生率最高，为65.7%，其次为恶心、呕吐及白细胞计数下降，但均以Ⅰ度为主。结论吉西他滨联合顺铂动静脉化疗方案治疗晚期 NSCLC 的临床疗效良好，尤其对中央型肺癌、肺鳞癌患者临床疗效更好，且毒副作用较轻微。
目的：分析吉西他濱聯閤順鉑動靜脈化療方案治療晚期非小細胞肺癌（NSCLC）的臨床療效。方法選擇恩施土傢族苗族自治州中心醫院2010年1月—2013年6月收治的晚期 NSCLC 患者70例，所有患者入院後給予吉西他濱聯閤順鉑動靜脈化療方案：吉西他濱1 g/ m2聯閤順鉑50 mg/ m2行支氣管動脈灌註（BAI）治療，第1天；吉西他濱1 g/ m2靜脈滴註，第8天。28 d 為1箇化療週期，2箇化療週期後觀察患者臨床療效及化療期間毒副作用髮生情況，併分析不同解剖分型及病理分型患者的臨床療效。結果70例晚期 NSCLC 患者中完全緩解5例，部分緩解38例，疾病穩定19例，疾病進展8例，有效率為61.4%。鱗癌患者臨床療效優于腺癌患者（u =2.004，P =0.045）、中央型患者臨床療效優于週圍型患者（u =3.639，P =0.000）。化療期間患者胸痛髮生率最高，為65.7%，其次為噁心、嘔吐及白細胞計數下降，但均以Ⅰ度為主。結論吉西他濱聯閤順鉑動靜脈化療方案治療晚期 NSCLC 的臨床療效良好，尤其對中央型肺癌、肺鱗癌患者臨床療效更好，且毒副作用較輕微。
목적：분석길서타빈연합순박동정맥화료방안치료만기비소세포폐암（NSCLC）적림상료효。방법선택은시토가족묘족자치주중심의원2010년1월—2013년6월수치적만기 NSCLC 환자70례，소유환자입원후급여길서타빈연합순박동정맥화료방안：길서타빈1 g/ m2연합순박50 mg/ m2행지기관동맥관주（BAI）치료，제1천；길서타빈1 g/ m2정맥적주，제8천。28 d 위1개화료주기，2개화료주기후관찰환자림상료효급화료기간독부작용발생정황，병분석불동해부분형급병리분형환자적림상료효。결과70례만기 NSCLC 환자중완전완해5례，부분완해38례，질병은정19례，질병진전8례，유효솔위61.4%。린암환자림상료효우우선암환자（u =2.004，P =0.045）、중앙형환자림상료효우우주위형환자（u =3.639，P =0.000）。화료기간환자흉통발생솔최고，위65.7%，기차위악심、구토급백세포계수하강，단균이Ⅰ도위주。결론길서타빈연합순박동정맥화료방안치료만기 NSCLC 적림상료효량호，우기대중앙형폐암、폐린암환자림상료효경호，차독부작용교경미。
Objective To analyze the clinical effect of arteriovenous chemotherapy of gemcitabine combined with cisplatin on advanced NSCLC. Methods A total of 70 patients with advanced NSCLC were selected in the Central Hospital of Tujia and Miao Enshi Autonomous Prefecture from January 2010 to June 2013,all of them received arteriovenous chemotherapy of gemcitabine combined with cisplatin after admission:on the first day,received bronchial artery infusion of gemcitabine(1 g/m2 )and cisplatin(50 mg/ m2 );on the eighth day,received intravenous drip of gemcitabine(1 g/ m2 ),treated for 2 cycles of chemotherapy( 28 days as a cycle of chemotherapy ). Clinical effect and incidence of toxic and side effects during chemotherapeutic period were observed,and clinical effect in patients with different anatomical types and pathological types were analyzed. Results Of the 70 patients,5 cases got complete remission,38 cases got partial remission,19 cases got stable disease,8 cases got progressive disease,the effective rate was 61. 4% . The clinical effect of patients with squamous carcinoma got better clinical effect than those patients with adenocarcinoma(u = 2. 004,P = 0. 045),and clinical effect of patients with central lung cancer got better clinical effect than those patients with peripheral lung cancer( u = 3. 639,P = 0. 000). The incidence of chest pain was in the first place(that was 65. 7% ),secondly were nausea,emesis and decrease of white blood cell count,most of them were at Ⅰ grade. Conclusion Arteriovenous chemotherapy of gemcitabine combined with cisplatin has good clinical effect in treating advanced NSCLC,especially in treating patients with squamous carcinoma or central lung cancer, and the toxic and side effects are mild.
